Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fezagepras sodium (Setogepram sodium salt) is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 60.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 239.00 | |
25 mg | In stock | $ 448.00 | |
50 mg | In stock | $ 669.00 | |
100 mg | In stock | $ 953.00 | |
500 mg | In stock | $ 1,920.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 162.00 |
Description | Fezagepras sodium (Setogepram sodium salt) is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions. |
In vitro | PBI-4050 inhibited kidney macrophage infiltration, oxidative stress, and TGF-β-mediated fibrotic signaling pathways, and it also protected against the development of tubulointerstitial fibrosis. To confirm a direct antiinflammatory/antifibrotic effect in the kidney, further studies with a nondiabetic model of EGFR-mediated proximal tubule activation confirmed that PBI-4050 dramatically decreased the development of the associated tubulointerstitial injury and macrophage infiltration[1]. |
In vivo | eNOS-/- db/db mice were treated with PBI-4050 from 8-20 weeks of age (early treatment) or from 16-24 weeks of age (late treatment). PBI-4050 treatment ameliorated the fasting hyperglycemia and abnormal glucose tolerance tests seen in vehicle-treated mice. In addition, PBI-4050 preserved (early treatment) or restored (late treatment) blood insulin levels and increased autophagy in islets. PBI-4050 treatment led to significant improvements in lifespan in the diabetic mice. Both early and late PBI-4050 treatment protected against progression of DN, as indicated by reduced histological glomerular injury and albuminuria, slow decline of glomerular filtration rate, and loss of podocytes[1]. |
Synonyms | Setogepram sodium salt, PBI-4050 sodium salt |
Molecular Weight | 228.26 |
Formula | C13H17NaO2 |
CAS No. | 1254472-97-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 90.0 mg/mL (394.3 mM)
DMSO: 57.6 mg/mL (252.3 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fezagepras sodium 1254472-97-3 Endocrinology/Hormones GPCR/G Protein GPR Setogepram sodium Setogepram sodium salt PBI-4050 sodium PBI-4050 sodium salt inhibitor inhibit